Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Recommendation of "Buy" by Brokerages

Key Points

• Analysts maintain a bullish view: Trevi Therapeutics has an average “Buy” rating from 13 research firms, with a consensus 12-month price target of $27.08. Recent target increases included B. Riley to $31, HC Wainwright to $24, and JonesTrading to $28, while Raymond James retained a $40 strong-buy target.
• Insider activity was negative: Director Michael Heffernan sold 39,473 shares for approximately $595,648, reducing his position by 86.14%; insiders own 15.39% of the company.
• Trevi is developing Haduvio for chronic cough associated with idiopathic pulmonary fibrosis and refractory chronic cough. The company met its latest quarterly EPS consensus at a loss of $0.11 per share, while analysts expect a full-year loss of $0.48 per share.

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) has been given an average rating of "Buy" by the thirteen research firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, ten have given a buy rating and two have given a strong buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $27.0833.

Several equities analysts have recently commented on TRVI shares. B. Riley Financial raised their price target on Trevi Therapeutics from $21.00 to $31.00 and gave the company a "buy" rating in a research note on Monday, July 20th. HC Wainwright increased their target price on shares of Trevi Therapeutics from $21.00 to $24.00 and gave the stock a "buy" rating in a report on Monday, July 20th. Raymond James Financial restated a "strong-buy" rating and issued a $40.00 price target on shares of Trevi Therapeutics in a report on Friday, August 7th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Trevi Therapeutics in a research report on Friday, July 17th. Finally, JonesTrading lifted their price objective on shares of Trevi Therapeutics from $24.00 to $28.00 and gave the company a "buy" rating in a report on Friday, August 14th.

Insiders Place Their Bets

In other Trevi Therapeutics news, Director Michael Heffernan sold 39,473 shares of the stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $15.09, for a total transaction of $595,647.57. Following the sale, the director owned 6,351 shares of the company's stock, valued at approximately $95,836.59. This trade represents a 86.14% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 15.39% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. KBC Group NV bought a new stake in Trevi Therapeutics during the first quarter valued at about $29,000. Hilton Head Capital Partners LLC purchased a new position in Trevi Therapeutics in the fourth quarter valued at about $40,000. Caitong International Asset Management Co. Ltd bought a new position in Trevi Therapeutics in the fourth quarter worth about $50,000. Avidity Partners Management LP purchased a new stake in shares of Trevi Therapeutics during the first quarter valued at about $79,000. Finally, Seven Fleet Capital Management LP purchased a new stake in shares of Trevi Therapeutics during the fourth quarter valued at about $89,000. 95.76% of the stock is owned by institutional investors.

Trevi Therapeutics Price Performance

Shares of TRVI stock opened at $14.95 on Friday. The company has a market capitalization of $2.13 billion, a P/E ratio of -43.97 and a beta of 1.04. The company's 50-day simple moving average is $17.48 and its two-hundred day simple moving average is $15.32. Trevi Therapeutics has a one year low of $8.04 and a one year high of $20.22.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.11). On average, research analysts expect that Trevi Therapeutics will post -0.48 EPS for the current fiscal year.

About Trevi Therapeutics

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for chronic cough and other conditions involving dysregulated sensory nerve activity. The company's lead product candidate is Haduvio, an oral extended-release formulation of nalbuphine designed to reduce chronic cough through activity at opioid receptors.

Trevi is studying Haduvio for chronic cough associated with idiopathic pulmonary fibrosis, a progressive lung disease, as well as refractory chronic cough, a condition in which coughing persists despite treatment of underlying causes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.